DBCA, 5-dimethylsulfamoyl-6,7-dichloro-2,3-dihydrobenzofuran-2- carboxylic acid, is a racemic antonio compound. Its stereoselective pharmacokinetics was suggested to be attributed to stereoselective hepatic and renal elimination based on in vivo studies. We have tried to clarify and estimate the stereoselectivity of hepatic and renal elimination by using of single-pass perfused organ preparations. Liver perfusion study of racemic DBCA showed R(+)-predominant extraction and generation of MBCA, 5monomethylsulfamoyl-6,7-dichloro-2,3-dihydrobenzofuran-2-carboxylic acid, the major metabolite of DBCA. Pharmacokinetic analysis based on a well- stirred model with diffusional clearance (CLd) across the sinusoidal membrane revealed the possibility of stereoselectivity not in the biliary excretion but in the hepatic transport and N-monodemethylation (R(+)-predominant). A single-pass kidney perfusion study under constant perfusion pressure indicated highly selective elimination for (R)(+)-DBCA. Plotting of fractional excretion (FE) ratios of DBCA enantiomers to (R)(+).MBCA against that of (R)(+)-MBCA suggests that the actual FE for (R)(+)-DBCA is two times larger than that for (S)(-)-DBCA. Thus, DBCA seemed to be stereoselectively secreted in the proximal tubules, although little information is available on the stereoselective renal secretion of acidic chiral compounds. Moreover, we also tried to clarify the stereoselective process in the renal tubular secretion of organic anions in the use of MBCA not metabolized further and the stereoselective uptake of MBCA from the basolateral membrane could be testified by the multiple indicator dilution studies using the isolated perfused kidney.
|Number of pages||38|
|Journal||Annual Report of Shionogi Research Laboratory|
|Publication status||Published - Dec 1 1996|
ASJC Scopus subject areas